

Serial antiarrhythmic drug treatment to maintain sinus cardioversion for chronic atrial fibrillation or atrial flutter

American Journal of Cardiology

68, 335-341

DOI: [10.1016/0002-9149\(91\)90828-9](https://doi.org/10.1016/0002-9149(91)90828-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Atrial Fibrillation: New Findings About an Old Nemesis. <i>Hospital Practice</i> (1995), 1991, 26, 75-88.	0.5	0
2	Evolving Strategies for the Management of Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 3332.	3.8	6
3	Low-Dose Amiodarone for Maintenance of Sinus Rhythm After Cardioversion of Atrial Fibrillation or Flutter. <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 3289.	3.8	213
4	Current therapy for supraventricular tachycardia. <i>Current Problems in Cardiology</i> , 1992, 17, 414-477.	1.1	10
5	Atrial fibrillation: New management strategies. <i>Current Problems in Cardiology</i> , 1993, 18, 237-300.	1.1	10
6	Antiarrhythmic drugs in the management of atrial fibrillation.. <i>Heart</i> , 1993, 70, 304-306.	1.2	10
7	Sotalol: A Novel Beta-Blocker with Class III Anti-Arrhythmic Activity. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 508-512.	1.0	5
8	Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities.. <i>Circulation</i> , 1993, 88, 1045-1053.	1.6	185
9	Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.. <i>Circulation</i> , 1994, 90, 2032-2040.	1.6	100
10	A consensus report on antiarrhythmic drug use. <i>Clinical Cardiology</i> , 1994, 17, 103-116.	0.7	39
11	Catheter Based Atrial Defibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1058-1066.	0.5	18
12	Atrial Fibrillation: The Next Frontier. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1203-1207.	0.5	8
13	Comparison of biphasic and monophasic waveforms in epicardial atrial defibrillation. <i>Journal of the American College of Cardiology</i> , 1994, 24, 171-176.	1.2	28
14	The Treatment of Atrial Fibrillation. <i>Drugs</i> , 1994, 48, 345-371.	4.9	83
15	Benefits and Risks of Antiarrhythmic Drug Therapy after DC Electrical Cardioversion of Atrial Fibrillation or Flutter. <i>European Heart Journal</i> , 1994, 15, 17-21.	1.0	36
16	Cardioversion of Atrial Fibrillation: How Important is a Long Arrhythmia Duration?. <i>Scottish Medical Journal</i> , 1994, 39, 78-79.	0.7	0
17	Implantable Atrial Defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 634-648.	0.8	24
18	Treatment of Resistant Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 1995, 155, 1885.	4.3	54

#	ARTICLE	IF	CITATIONS
19	Cardioversion of atrial fibrillation. Postgraduate Medical Journal, 1995, 71, 457-465.	0.9	43
20	Newer developments in the management of atrial fibrillation. American Heart Journal, 1995, 130, 1094-1106.	1.2	87
21	Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. Journal of the American College of Cardiology, 1995, 25, 1347-1353.	1.2	223
22	Management of Atrial Fibrillation in Adults: Prevention of Thromboembolism and Symptomatic Treatment. Mayo Clinic Proceedings, 1996, 71, 150-160.	1.4	57
23	ANTIARRHYTHMIC DRUG THERAPY IN THE TREATMENT OF ATRIAL FIBRILLATION. Cardiology Clinics, 1996, 14, 507-520.	0.9	19
24	THERAPEUTIC STRATEGIES FOR ATRIAL FIBRILLATION. Cardiology Clinics, 1996, 14, 623-640.	0.9	8
25	References / Subject Index. Advances in Cardiology, 1996, 38, 145-168.	2.6	0
26	Atrial Fibrillation in the Elderly. Clinical Cardiology, 1996, 19, 765-775.	0.7	29
27	Efficacy of serial electrical cardioversion therapy in patients with chronic atrial fibrillation after valve replacement and implications for surgery to cure atrial fibrillation. American Journal of Cardiology, 1996, 78, 1140-1144.	0.7	19
28	Atrial fibrillation: Maintenance of sinus rhythm versus rate control. American Journal of Cardiology, 1996, 77, 24A-37A.	0.7	106
29	Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a multicenter trial. American Journal of Cardiology, 1996, 77, 72A-82A.	0.7	47
30	Control of Rapid Heart Rate in Patients with Atrial Fibrillation: Drugs or Ablation?. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 348-356.	0.5	27
31	Is the Automatic Atrial Defibrillator a Promising Approach?. Journal of Cardiovascular Electrophysiology, 1996, 7, 1217-1224.	0.8	11
32	New Approaches to Treatment of Atrial Flutter and Tachycardia. Journal of Cardiovascular Electrophysiology, 1996, 7, 368-381.	0.8	31
33	Chronic Atrial Fibrillation. Archives of Internal Medicine, 1996, 156, 2585.	4.3	154
34	Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks.. Heart, 1996, 75, 635-638.	1.2	41
35	The antiarrhythmic treatment of atrial fibrillation. Drug and Therapeutics Bulletin, 1996, 34, 41-45.	0.3	3
36	Long-term outcome of electrical cardioversion in patients with chronic atrial flutter.. Heart, 1997, 77, 56-61.	1.2	36

#	ARTICLE	IF	CITATIONS
37	Atrial fibrillation begets trouble.. Heart, 1997, 77, 393-394.	1.2	19
38	Nonpharmacologic Treatment of Atrial Fibrillation. Chest, 1997, 112, 1079-1090.	0.4	9
39	THE MEDICAL MANAGEMENT OF ATRIAL FIBRILLATION. Cardiology Clinics, 1997, 15, 689-719.	0.9	14
40	Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. American Heart Journal, 1997, 134, 155-160.	1.2	13
41	Management of the patient in atrial fibrillation. Evidence-based Cardiovascular Medicine, 1997, 1, 59-60.	0.0	0
42	Comparision of thr Efficacy of Propafenone and Flecainide in Patients with Atrial Fibrillation. Sunhwan'gi, 1997, 27, 860.	0.3	2
43	Antiarrhythmic Drug Therapy in the Management of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 1997, 8, 1175-1189.	0.8	34
44	Low-Energy Transvenous Cardioversion of Atrial Fibrillation Using a Single Atrial Lead System. Journal of Cardiovascular Electrophysiology, 1997, 8, 607-617.	0.8	14
45	Efficacy, Safety, and Determinants of Conversion of Atrial Fibrillation and Flutter With Oral Amiodarone. American Journal of Cardiology, 1997, 79, 53-57.	0.7	106
46	Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful directâ€current cardioversion. Clinical Cardiology, 1997, 20, 337-340.	0.7	66
47	Rhythm Management in Atrial Fibrillation-With a Primary Emphasis on Pharmacologic Therapy: Part 3. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1133-1145.	0.5	22
48	Progression of Permanent Atrial Fibrillation After Atrioventricular Junction Ablation and Dual-Chamber Pacemaker Implantation in Patients With Paroxysmal Atrial Tachyarrhythmias. American Journal of Cardiology, 1998, 81, 351-354.	0.7	43
49	Acute Treatment of Atrial Fibrillation: Why and When to Maintain Sinus Rhythm. American Journal of Cardiology, 1998, 81, 3C-15C.	0.7	69
50	Frequency Analysis of Human Atrial Fibrillation Using the Surface Electrocardiogram and Its Response to Ibutilide. American Journal of Cardiology, 1998, 81, 1439-1445.	0.7	249
51	Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. American Journal of Cardiology, 1998, 82, 72N-81N.	0.7	15
52	Progress toward a catheter ablative cure of atrial fibrillation. Journal of Electrocardiology, 1998, 31, 71-79.	0.4	4
53	Spectral analysis of the electrocardiogram predicts recurrence of atrial fibrillation after cardioversion. Journal of Electrocardiology, 1998, 31, 80-84.	0.4	22
54	Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response. Archives of Gerontology and Geriatrics, 1998, 27, 127-139.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Early Recurrences of Atrial Fibrillation After Electrical Cardioversion: A Result of Fibrillation-Induced Electrical Remodeling of the Atria?. Journal of the American College of Cardiology, 1998, 31, 167-173.	1.2	330
57	Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. American Heart Journal, 1998, 135, 551-556.	1.2	24
58	Treatment Strategies for Atrial Fibrillation. American Journal of Medicine, 1998, 104, 272-286.	0.6	68
59	Current Treatment Recommendations in Antiarrhythmic Therapy. Drugs, 1998, 55, 331-346.	4.9	16
60	Clinical Pharmacology of Antiarrhythmic Drugs. Drugs and Aging, 1998, 13, 51-70.	1.3	9
61	The Use of Drugs for Cardioversion of Recent Onset Atrial Fibrillation and Flutter. Drugs and Aging, 1998, 12, 461-476.	1.3	5
62	Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?. Journal of Cardiovascular Pharmacology and Therapeutics, 1998, 3, 185-194.	1.0	1
63	Atrial fibrillation: current knowledge and recommendations for management*1. European Heart Journal, 1998, 19, 1294-1320.	1.0	271
64	Ablate and pace: a pragmatic approach to paroxysmal atrial fibrillation not controlled by antiarrhythmic drugs. Heart, 1998, 79, 531-533.	1.2	11
65	Positive inotropic drugs and drugs used in dysrhythmias. Side Effects of Drugs Annual, 1998, 21, 194-206.	0.6	0
66	4. Atrial fibrillation. Medical Journal of Australia, 1999, 170, 498-504.	0.8	2
67	Alterations in atrial electrophysiology associated with chronic atrial fibrillation in man. European Heart Journal, 1999, 20, 888-895.	1.0	43
68	Prospective, randomized study of atrioventricular ablation and mode-switching, dual chamber pacemaker implantation versus medical therapy in drug-resistant paroxysmal atrial fibrillation. Europace, 1999, 1, 15-19.	0.7	22
69	Cardioversion for atrial fibrillation: the views of consultant physicians, geriatricians and cardiologists. Age and Ageing, 1999, 28, 73-75.	0.7	10
70	Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. Europace, 1999, 1, 234-241.	0.7	30
71	Determinants of development of permanent atrial fibrillation and its treatment. Europace, 1999, 1, 35-39.	0.7	13
72	Assessment of Atrioventricular Junction Ablation and VVIR Pacemaker Versus Pharmacological Treatment in Patients With Heart Failure and Chronic Atrial Fibrillation. Circulation, 1999, 99, 2966-2968.	1.6	19
73	Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart, 1999, 82, 486-493.	1.2	25

#	ARTICLE	IF	CITATIONS
74	Atrial fibrillation: prevalence and management in an acute general medical unit. Australian and New Zealand Journal of Medicine, 1999, 29, 51-58.	0.5	31
75	Low Energy Internal Atrial Cardioversion in Atrial Fibrillation Lasting More Than a Year. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 243-246.	0.5	19
76	Optimal Management with Class I and Class III Antiarrhythmic Drugs Should Be Done in the Outpatient Setting.. Journal of Cardiovascular Electrophysiology, 1999, 10, 472-481.	0.8	23
77	Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion. American Journal of Cardiology, 1999, 83, 607-609.	0.7	15
78	Discussion. American Journal of Cardiology, 1999, 84, 698-700.	0.7	35
79	Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. American Journal of Cardiology, 1999, 84, 161-173.	0.7	27
80	Second Line Pharmacological Management of Paroxysmal and Persistent Atrial Fibrillation in France: A Cost Analysis. Value in Health, 2000, 3, 407-416.	0.1	20
81	Therapy of Atrial Fibrillation: Rhythm Control Versus Rate Control. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 891-903.	0.5	25
82	Failure of Coronary Sinus Pacing in Reducing Local Atrial Conduction Delay in Patients with Atrial Fibrillation After Successful Internal Cardioversion. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1014-1019.	0.5	1
83	Atrial fibrillation: Epidemiology, mechanisms, and management. Current Problems in Cardiology, 2000, 25, 413-524.	1.1	16
84	Ablate and pace: palliating the symptoms?. American Journal of Cardiology, 2000, 86, K4-K8.	0.7	8
85	Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. American Journal of Cardiology, 2000, 86, 1327-1332.	0.7	12
86	Novel catheter technology for ablative cure of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 127-139.	0.6	19
87	The AFFIRM trial: main trial and substudies-what can We expect?. , 2000, 4, 171-176.		28
89	Atrial fibrillation. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 281-295.	0.4	2
90	Clinical Outcomes After Ablation and Pacing Therapy for Atrial Fibrillation. Circulation, 2000, 101, 1138-1144.	1.6	446
91	Systematic review of the management of atrial fibrillation in patients with heart failure. European Heart Journal, 2000, 21, 614-632.	1.0	116
92	Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. European Heart Journal, 2000, 21, 66-73.	1.0	125

#	ARTICLE	IF	CITATIONS
93	Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo-controlled, multicenter study. <i>American Heart Journal</i> , 2000, 140, 437-444.	1.2	30
94	Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: A single-blind, randomized, controlled study. <i>American Heart Journal</i> , 2000, 140, 437-443.	1.2	40
95	Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. <i>Journal of the American College of Cardiology</i> , 2001, 37, 157-162.	1.2	121
96	Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1403-1407.	1.2	40
97	Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. <i>Journal of the American College of Cardiology</i> , 2001, 38, 883-891.	1.2	277
98	Pharmacologic management of atrial fibrillation: Current therapeutic strategies. <i>American Heart Journal</i> , 2001, 141, S15-S21.	1.2	38
99	Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. <i>International Journal of Cardiology</i> , 2001, 81, 29-35.	0.8	44
101	Current Management of Symptomatic Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 127-139.	1.0	5
102	Antiarrhythmic Agents in Facilitating Electrical Cardioversion of Atrial Fibrillation and Promoting Maintenance of Sinus Rhythm. <i>Cardiology</i> , 2001, 95, 1-8.	0.6	24
103	A Survey of Long-Term Antiarrhythmic Therapy in Elderly Patients with Atrial Fibrillation. <i>Journal of Pharmacy Practice and Research</i> , 2001, 31, 93-97.	0.2	3
104	Paroxysmal atrial fibrillation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2001, 94, 665-678.	0.2	75
105	Hochfrequenz-Katheterablation zur Therapie von Vorhofflimmern. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2001, 12, 95-102.	0.3	0
106	Internal Low Energy Atrial Cardioversion: Efficacy and Safety in Older Patients with Chronic Persistent Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 80-84.	1.3	2
107	Comparison Of Digoxin Versus Low-Dose Amiodarone For Ventricular Rate Control In Patients With Chronic Atrial Fibrillation. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 446-450.	0.9	43
108	factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. <i>Clinical Cardiology</i> , 2001, 24, 238-244.	0.7	122
109	Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. <i>Clinical Cardiology</i> , 2001, 24, 503-505.	0.7	5
110	Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. <i>American Journal of Cardiology</i> , 2001, 87, 172-177.	0.7	16
111	Electrophysiologic and Antiarrhythmic Effects of the New Class III Antiarrhythmic Drug KCB-328 in Experimental Canine Atrial Flutter. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2001, 6, 297-306.	1.0	8

#	ARTICLE	IF	CITATIONS
112	External cardioversion of atrial fibrillation: comparison of biphasic vs monophasic waveform shocks. <i>Europace</i> , 2001, 3, 96-99.	0.7	48
113	Acute pressure overload cardiac arrhythmias are dependent on the presence of myocardial tissue catecholamines. <i>British Heart Journal</i> , 2001, 85, 576-576.	2.2	17
114	Long-Term Survival after Ablation of the Atrioventricular Node and Implantation of a Permanent Pacemaker in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2001, 344, 1043-1051.	13.9	297
115	Atrial Pacing for the Prevention and Termination of Atrial Fibrillation. <i>The American Journal of Geriatric Cardiology</i> , 2002, 11, 380-398.	0.7	8
116	A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2002, 347, 1825-1833.	13.9	4,017
117	What is the optimal electrode configuration for atrial defibrillators in man?. <i>Europace</i> , 2002, 4, 41-44.	0.7	11
118	Management of Atrial Fibrillation â€” Radical Reform or Modest Modification?. <i>New England Journal of Medicine</i> , 2002, 347, 1883-1884.	13.9	36
119	Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm. A randomized study. <i>European Heart Journal</i> , 2002, 23, 1522-1528.	1.0	35
120	â€œPills and Pulsesâ€ Hybrid Therapy for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, S40-6.	0.8	14
121	Atrial Fibrillation in the Elderly. <i>Drugs and Aging</i> , 2002, 19, 819-846.	1.3	58
122	Atrial size and transport function after the Maze III procedure for paroxysmal atrial fibrillation. <i>Annals of Thoracic Surgery</i> , 2002, 73, 107-111.	0.7	34
123	Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. <i>American Heart Journal</i> , 2002, 143, 991-1001.	1.2	157
127	Atrial Fibrillation and Congestive Heart Failure: Specific Considerations at the Intersection of Two Common and Important Cardiac Disease Sets. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 399-405.	0.8	182
128	Prevention of and medical therapy for atrial arrhythmias in heart failure. <i>Heart Failure Reviews</i> , 2002, 7, 267-283.	1.7	13
129	Recent Advances in Drug Therapy for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S40-S47.	0.8	21
130	Clinical Predictors and Time Course of Arrhythmia Recurrence in Patients with Early Reinitiation of Atrial Fibrillation After Successful Internal Cardioversion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 1809-1814.	0.5	5
131	Matrix metalloproteinases and atrial structural remodeling**Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the author and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2003, 42, 345-347.	1.2	26
132	Pharmacologic Reversion of Persistent Atrial Fibrillation with Amiodarone Predicts Long-Term Sinus Rhythm Maintenance. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003, 8, 179-186.	1.0	12

#	ARTICLE	IF	CITATIONS
133	Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation Results of a prospective and controlled study. European Heart Journal, 2003, 24, 2090-2098.	1.0	257
134	Treatment of atrial fibrillation with an implantable atrial defibrillator â€” long term results. European Heart Journal, 2003, 24, 2083-2089.	1.0	41
136	Rate or rhythm control in persistent atrial fibrillation?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 881-892.	0.2	26
137	Effect of Pulmonary Vein Isolation on Quality of Life in Patients with Paroxysmal Atrial Fibrillation. Cardiology, 2003, 3, 173-179.	0.3	2
138	Atrial Fibrillation: Rhythm Control or Rate Control â€” Which Strategy is Preferred?. Hospital Pharmacy, 2004, 39, 17-22.	0.4	0
139	Cardioversion of uncomplicated paroxysmal atrial fibrillation: a survey of practice by Canadian emergency physicians. Canadian Journal of Emergency Medicine, 2004, 6, 155-160.	0.5	14
140	Pacing for Prevention of Atrial Fibrillation: Fact or Fancy. , 0, , 44-50.		0
142	Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 2004, 109, 1973-1980.	1.6	215
143	Temporal changes in atrial refractoriness following DC cardioversion of persistent atrial fibrillation in man. Europace, 2004, 6, 229-235.	0.7	1
144	Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension*1. Europace, 2004, 6, 343-350.	0.7	39
145	Rate Control vs Rhythm Control in Patients With Nonvalvular Persistent Atrial Fibrillation. Chest, 2004, 126, 476-486.	0.4	438
147	Rate versus rhythm control in atrial fibrillation. Cardiology Clinics, 2004, 22, 63-69.	0.9	18
148	Radiofrequency ablation of atrial fibrillation. International Journal of Cardiology, 2004, 93, 231-237.	0.8	5
149	Efficacy of internal cardioversion for chronic atrial fibrillation in patients with and without left ventricular dysfunction. International Journal of Cardiology, 2004, 95, 43-47.	0.8	10
150	Implications for Nursing Care of Patients With Atrial Fibrillation. Journal of Cardiovascular Nursing, 2004, 19, 128-137.	0.6	7
151	Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 797-802.	0.4	371
152	Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2005, 293, 2634.	3.8	984
153	Atrial Myocardial Deformation Properties Predict Maintenance of Sinus Rhythm After External Cardioversion of Recent-Onset Lone Atrial Fibrillation. Circulation, 2005, 112, 387-395.	1.6	243

#	ARTICLE	IF	CITATIONS
154	Serial Antiarrhythmic Therapy: Role of Amiodarone in Prevention of Atrial Fibrillation Recurrence â€” A Lesson from the HOT CAFE Polish Study. <i>Cardiology</i> , 2005, 104, 35-44.	0.6	4
155	Impact of atrial fibrillation duration on postcardioversion recurrence. <i>Heart Rhythm</i> , 2005, 2, 1324-1329.	0.3	15
156	Atrial Fibrillation and Atrial Fibrillation Intervalsâ€”Frequency Analysis and Interpretationâ€”. <i>Journal of Arrhythmia</i> , 2005, 21, 495-509.	0.5	1
157	Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study. <i>American Heart Journal</i> , 2005, 149, 304-308.	1.2	23
158	Assessing Atrial Mechanical Remodeling and Its Consequences. <i>Circulation</i> , 2005, 112, 304-306.	1.6	34
159	Implication from Randomized Trials of Rate and Rhythm Controls on Management of Patients with Persistent Atrial Fibrillation. <i>Annals of Noninvasive Electrocardiology</i> , 2006, 11, 170-186.	0.5	1
160	Ablation of Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2006, 31, 361-390.	1.1	25
161	Results From the Loire-Ardèche-Drôme-Iseère-Puy-de-Dôme (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter. <i>Circulation</i> , 2006, 114, 1676-1681.	1.6	120
162	Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation. <i>Europace</i> , 2007, 9, 942-946.	0.7	19
163	Management of atrial fibrillation. <i>Lancet, The</i> , 2007, 370, 604-618.	6.3	205
165	Electrical Cardioversion for AF?The State of the Art. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 554-567.	0.5	40
166	Relation of C-Reactive Protein to Long-Term Risk of Recurrence of Atrial Fibrillation After Electrical Cardioversion. <i>American Journal of Cardiology</i> , 2007, 99, 1421-1424.	0.7	62
167	Malabsorption causing failure of pharmacological therapy in the treatment of atrial fibrillation. <i>International Journal of Cardiology</i> , 2008, 128, e87-e88.	0.8	1
168	Intraoperative Modified Cox Mini-Maze Procedure for Long-Standing Persistent Atrial Fibrillation. <i>Annals of Thoracic Surgery</i> , 2008, 85, 1283-1289.	0.7	17
169	Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. <i>Cardiovascular Pathology</i> , 2008, 17, 318-324.	0.7	46
170	Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF). <i>Canadian Journal of Cardiology</i> , 2008, 24, 709-713.	0.8	20
171	Acute and clinical effects of cryoballoon pulmonary vein isolation in patients with symptomatic paroxysmal and persistent atrial fibrillation. <i>Europace</i> , 2008, 10, 1277-1280.	0.7	52
173	MRI in cardiac electrophysiology: the emerging role of delayed-enhancement MRI in atrial fibrillation ablation. <i>Future Cardiology</i> , 2009, 5, 63-70.	0.5	9

#	ARTICLE	IF	CITATIONS
174	Trends in catheter ablation for atrial fibrillation in the United States. <i>Journal of Hospital Medicine</i> , 2009, 4, E1-5.	0.7	88
175	Left atrial asynchrony is a major predictor of 1-year recurrence of atrial fibrillation after electrical cardioversion. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 499-506.	0.6	27
177	First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes. <i>International Journal of Clinical Practice</i> , 2010, 64, 1062-1068.	0.8	4
179	Atrial asynchrony and function before and after electrical cardioversion for persistent atrial fibrillation. <i>European Journal of Echocardiography</i> , 2010, 11, 577-583.	2.3	74
180	Very Low Risk of Thromboembolic Events in Patients Undergoing Successful Catheter Ablation of Atrial Fibrillation With a CHADS ₂ Score \leq 3. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 615-621.	2.1	107
181	Segurança da ablação de fibrilação atrial com RNI terapêutico: comparação com a transição com heparina de baixo peso. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 97, 289-296.	0.3	9
182	The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. <i>Journal of Internal Medicine</i> , 2011, 270, 281-290.	2.7	34
183	Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2011, 13, 543-550.	2.9	28
184	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. <i>Europace</i> , 2011, 13, 1517-1525.	0.7	55
185	Role of inflammation in early atrial fibrillation recurrence. <i>Europace</i> , 2012, 14, 810-817.	0.7	79
186	Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2013, 10, 696-701.	0.3	41
188	The mechanical fibrillation pattern of the atrial myocardium is associated with acute and long-term success of electrical cardioversion in patients with persistent atrial fibrillation. <i>Heart Rhythm</i> , 2014, 11, 1514-1521.	0.3	7
189	Effect of sinus rhythm restoration on platelet function in patients with lone atrial fibrillation. <i>International Journal of Cardiology</i> , 2014, 172, e22-e23.	0.8	10
190	Atrial Fibrillation Therapies: Lest We Forget Surgery. <i>Canadian Journal of Cardiology</i> , 2014, 30, 590-597.	0.8	6
191	Maintenance of sinus rhythm after electrical cardioversion for recurrent atrial fibrillation following mitral valve surgery with or without associated radiofrequency ablation. <i>International Journal of Cardiology</i> , 2014, 175, 290-296.	0.8	4
192	Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 42, 117-124.	0.6	6
193	Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 549-567.	0.8	166
194	Is SYNTAX Score Predictive of Atrial Fibrillation after On-Pump Coronary Artery Bypass Graft Surgery?. <i>Korean Circulation Journal</i> , 2016, 46, 798.	0.7	14

#	ARTICLE	IF	CITATIONS
195	Thoracoscopic Ablation with Appendage Ligation versus Medical Therapy for Stroke Prevention a Proof-of-Concept Randomized Trial. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2016, 11, 99-105.	0.4	10
196	Flecainide+metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. <i>Europace</i> , 2016, 18, 1698-1704.	0.7	23
197	Chicken or the egg: ST elevation in lead aVR or SYNTA X score. <i>Cardiovascular Journal of Africa</i> , 2017, 28, 100-103.	0.2	8
198	Patients with atrial fibrillation and coronary artery disease – Double trouble. <i>Advances in Medical Sciences</i> , 2018, 63, 30-35.	0.9	142
199	Patients with Atrial Fibrillation and Chronic Kidney Disease More Often Undergo Angioplasty of Left Main Coronary Artery – a 867 Patient Study. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 1796-1805.	0.9	3
200	Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. <i>American Journal of Medicine</i> , 2018, 131, 1075-1085.e4.	0.6	15
201	Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13161.	1.7	5
202	Paradigm shifts in pathophysiology and management of atrial fibrillation – a tale of the RACE trials in the Netherlands. <i>Netherlands Heart Journal</i> , 2020, 28, 3-12.	0.3	5
203	Prevalence of Coronary Artery Calcium in Patients With Atrial Fibrillation With and Without Cardiovascular Risk Factors. <i>American Journal of Cardiology</i> , 2020, 125, 1765-1769.	0.7	9
204	Atrial high-rate episodes: a comprehensive review. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 48-53.	0.2	2
205	Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. <i>Archives of Internal Medicine</i> , 1996, 156, 2585-2592.	4.3	124
206	Nichtpharmakologische Behandlungsmethoden zur Frequenzkontrolle bei Vorhofflimmern. , 2000, , 171-195.		1
207	Drugs after Cardioversion to Prevent Relapses of Chronic Atrial Fibrillation or Flutter. <i>Developments in Cardiovascular Medicine</i> , 1992, , 105-148.	0.1	9
208	Anticoagulation for patients with atrial fibrillation. <i>BMJ: British Medical Journal</i> , 2000, 321, 638-638.	2.4	1
209	Non-invasive characterisation of coronary lesion morphology by multi-slice computed tomography: a promising new technology for risk stratification of patients with coronary artery disease. <i>British Heart Journal</i> , 2001, 85, 576a-578.	2.2	46
210	Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study. <i>British Heart Journal</i> , 2001, 85, 578-580.	2.2	11
211	Atrial Fibrillation Begets Atrial Fibrillation. <i>Circulation</i> , 1995, 92, 1954-1968.	1.6	2,931
212	Electrical Remodeling in Atrial Fibrillation. <i>Circulation</i> , 1996, 94, 2968-2974.	1.6	489

#	ARTICLE	IF	CITATIONS
213	Verapamil Reduces Tachycardia-Induced Electrical Remodeling of the Atria. <i>Circulation</i> , 1997, 95, 1945-1953.	1.6	283
214	Characterization of Low Right Atrial Isthmus as the Slow Conduction Zone and Pharmacological Target in Typical Atrial Flutter. <i>Circulation</i> , 1997, 96, 2601-2611.	1.6	73
215	Assessment of Atrioventricular Junction Ablation and DDDR Mode-Switching Pacemaker Versus Pharmacological Treatment in Patients With Severely Symptomatic Paroxysmal Atrial Fibrillation. <i>Circulation</i> , 1997, 96, 2617-2624.	1.6	207
216	Thoracoscopic Ablation with Appendage Ligation versus Medical Therapy for Stroke Prevention a Proof-of-Concept Randomized Trial. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2016, 11, 99-105.	0.4	3
217	Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography. <i>PLoS ONE</i> , 2011, 6, e24964.	1.1	198
218	I Diretriz da Sociedade Brasileira de Cardiologia Sobre Cardiologia Nuclear. <i>Arquivos Brasileiros De Cardiologia</i> , 0, 78, 1-42.	0.3	18
219	Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure. <i>Current Pharmaceutical Design</i> , 2014, 21, 1011-1029.	0.9	4
220	2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients. <i>Korean Journal of Medicine</i> , 2018, 93, 110-132.	0.1	6
221	Efficacy of Cox Maze IV Procedure Using Argon-Based Cryoablation: A Comparative Study with N ₂ O-Based Cryoablation. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 47, 367-372.	0.6	7
224	Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study. <i>Heart</i> , 2001, 85, 578-580.	1.2	0
225	Useful clinical features for the selection of ideal patients with atrial fibrillation for mapping and catheter ablation. <i>Arquivos Brasileiros De Cardiologia</i> , 2002, 78, 9-16.	0.3	11
226	Incidence and Diagnosis of Atrial Fibrillation in Patients with Heart Failure. , 2003, , 9-11.		0
227	Ablate and Pace: Is This Still a Valid Option?. , 2004, , 107-116.		0
228	Atrial Fibrillation and Atrial Fibrillation Intervals-Frequency Analysis and Interpretation-. <i>Journal of Arrhythmia</i> , 2005, 21, 495-509.	0.5	0
229	An Overview of Today's Techniques and Advances for Treating Atrial Fibrillation. <i>European Cardiology Review</i> , 2007, 3, 48.	0.7	0
230	Ectopic Foci Study on the Crest Terminalis in 3D Computer Model of Human Atrial. <i>Advances in Intelligent and Soft Computing</i> , 2012, , 157-164.	0.2	0
232	The effect of atrium diameter on the successful treatment of atrial fibrillation through the radiofrequency ablation technique. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 20, 503-509.	0.2	0
233	Indication of antiarrhythmic drugs and their problems. Significance of class 3 drugs for supraventricular arrhythmia. Clinical and electrophysiological effects of dofetilide, E4031.. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 1996, 27, 337-338.	0.1	0

#	ARTICLE	IF	CITATIONS
234	Control of Rapid Heart Rate in Patients with Atrial Fibrillation: Drugs or Ablation?. , 1996, , 236-241.		0
235	Severe Paroxysmal Atrial Fibrillation: Atrioventricular Junction Ablation and DDDR Mode-Switching Pacemaker Versus Pharmacological Treatment. Developments in Cardiovascular Medicine, 1998, , 29-34.	0.1	0
237	Evolution of Force Sensing Technologies. Arrhythmia and Electrophysiology Review, 2017, 6, 75.	1.3	1
238	Predictors of Failure Cardioversion for Recurrent Atrial Fibrillation Following Mitral Valve Surgery With Ablation. Heart Surgery Forum, 2020, 23, E300-E304.	0.2	0
241	A review of atrial fibrillation. Journal of the National Medical Association, 2002, 94, 1036-48.	0.6	4
242	Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis. Indian Pacing and Electrophysiology Journal, 2009, 9, 15-24.	0.3	5
243	Atrial Fibrillation Progression: New Insight in TheNatural History of This Arrhythmia. Journal of Atrial Fibrillation, 2009, 1, 156.	0.5	0
244	The Association Between Recurrence of Atrial Fibrillation and Revascularization in Patients With Coronary Artery Disease After Catheter Ablation. Frontiers in Cardiovascular Medicine, 2021, 8, 756552.	1.1	7
245	Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 2022, , .	0.7	0
246	Understanding Antiarrhythmic Drug Efficacy for the Clinical Practitioner: There Is More than Meets the Eye. American Journal of Medicine, 2022, 135, 822-827.	0.6	2
249	Evaluation of coronary artery disease in patients undergoing atrial fibrillation ablation: a non-invasive FFR computed tomography study. Heart and Vessels, 0, , .	0.5	1